Clinical trials: Temozolomide
Glioblastoma, Gliosarcoma
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Primary objective: To use overall survival to assess the efficacy of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan in the treatment of grade IV malignant glioma…
- Conditions
- Glioblastoma, Gliosarcoma, Brain Tumor
- Trial name
- NCT00597402
- Testing
- Avastin, Temozolomide, Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Duke University
Brain Cancer, Brain Neoplasm, Primary
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine…
- Conditions
- Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor
- Trial name
- RESIST (NCT02193347)
- Testing
- PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Katy Peters, MD, PhD
Malignant Glioma, Grade 4 Malignant Glioma
Bevacizumab Beyond Progression (BBP)
Studies which have separately studied bevacizumab for recurrent gliomas and bevacizumab for newly-diagnosed glioma have shown good results and the regimens have been well-tolerated by patients.
- Conditions
- Malignant Glioma, Grade 4 Malignant Glioma, Glioblastoma, Gliosarcoma
- Trial name
- BBP (NCT01740258)
- Testing
- Radiation Therapy, Temozolomide, Bevacizumab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Gliosarcoma
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
The primary objective of the study is to determine the efficacy of Avastin in combination with temozolomide and irinotecan in terms of response rate.
- Trial name
- NCT00979017
- Testing
- Avastin, Temozolomide, Irinotecan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Katy Peters
Melanoma, Metastatic Melanoma
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
The purpose of this study is to evaluate the efficacy of ABT-888 in combination with temozolomide versus temozolomide alone in subjects with metastatic melanoma.
- Conditions
- Melanoma, Metastatic Melanoma, Skin Cancer
- Trial name
- NCT00804908
- Testing
- temozolomide, ABT-888
- Volunteers
- 346 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
Malignant Glioma, Glioblastoma
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
This is a phase II study of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and topotecan in grade IV malignant glioma patients.
- Conditions
- Malignant Glioma, Glioblastoma, Gliosarcoma
- Trial name
- NCT01004874
- Testing
- Bevacizumab, Temozolomide, Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Duke University
Glioblastoma, Gliosarcoma
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
This is a phase II study of Bevacizumab plus Temodar and Tarceva in patients with non-progressive glioblastoma or gliosarcoma. Patients must have stable disease immediately following a standard course of up-front radiotherapy and…
- Trial name
- AVF4120s (NCT00525525)
- Testing
- Bevacizumab, Tarceva, Temozolomide
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco
Glioblastoma, Gliosarcoma
Dose-Intense Temozolomide in Recurrent Glioblastoma
Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas. In this study, we will be using temozolomide to treat recurrent glioblastomas.
- Trial name
- NCT00657267
- Testing
- Temozolomide
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- Patrick Y. Wen, MD
Melanoma
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
The purpose of this study is to ascertain if the extended schedule of Temozolomide, which allows increased doses and potential depletion of the enzyme underlaying resistance, is a more effective treatment of metastatic melanoma…
- Trial name
- NCT00091572
- Testing
- Temozolomide, Dacarbazine
- Volunteers
- 859 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain and Central Nervous System Tumors
Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing…
- Trial name
- NCT00990652
- Testing
- Bortezomib, Temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Metastatic Breast Cancer
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel…
- Trial name
- NCT01506609
- Testing
- Veliparib, Carboplatin, Temozolomide
- Where
- 120 sites in United States, Argentina and 18 more
- Volunteers
- 294 people
- Sponsor
- AbbVie
Breast Cancer, Brain Metastasis
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Background: Sometimes breast cancer spreads (metastasizes) to the brain. Researchers want to study new treatments for brain metastases. The drug Temozolomide is approved to treat brain tumors.
- Conditions
- Breast Cancer, Brain Metastasis, Brain Cancer
- Trial name
- NCT03190967
- Testing
- T-DM1, TMZ
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of pevonedistat when given together with irinotecan hydrochloride and temozolomide in treating patients with solid tumors, central nervous system (CNS) tumors, or lymphoma…
- Conditions
- Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma
- Trial name
- NCT03323034
- Testing
- Irinotecan, Pevonedistat, Temozolomide
- Where
- 20 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Oncology Group
Glioblastoma, Astrocytoma
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.
- Conditions
- Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Tumor, Recurrent
- Trial name
- NCT00575887
- Testing
- Temozolomide
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Marmara University
Melanoma, Skin Cancer
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
The investigators want to learn to predict which tumors will respond to CVT chemotherapy. CVT is a combination of three drugs - cisplatin, vinblastine, and temozolomide.
- Trial name
- NCT00885534
- Testing
- Cisplatin, Vinblastine, Temozolomide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioma, Anaplastic Astrocytoma
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches.
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT03072134
- Testing
- Neural stem cells loaded with an oncolytic adenovirus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
This phase II/III trial compares the effect of the combination treatment with olaparib and temozolomide to trabectedin or pazopanib (two of the most common chemotherapy drugs used as usual approach) in patients with uterine…
- Conditions
- Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
- Trial name
- NCT05432791
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 145 sites in United States, Puerto Rico
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
In this phase II trial the investigators plan to incorporate two targeted agents, bevacizumab and everolimus, into the first-line multimodality therapy of glioblastoma.
- Trial name
- NCT00805961
- Testing
- Radiation therapy, Temozolomide, Bevacizumab
- Where
- 13 sites in United States
- Volunteers
- 68 people
- Sponsor
- SCRI Development Innovations, LLC
Glioblastoma, Gliomas
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
Patients have a newly diagnosed brain tumor called a malignant glioma and participate in the study to see if it is possible to increase the benefit of temozolomide when given after radiation.
- Trial name
- NCT00200161
- Testing
- Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 127 people
- Sponsor
- Memorial Sloan Kettering Cancer Center